Literature DB >> 16901393

Clinical trials report. Minimal residual disease quantification in adult acute lymphoblastic leukemia.

Heather Landau, Mark A Weiss.   

Abstract

Entities:  

Year:  2006        PMID: 16901393     DOI: 10.1007/s11912-006-0053-1

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  5 in total

1.  Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia.

Authors:  J Brisco; E Hughes; S H Neoh; P J Sykes; K Bradstock; A Enno; J Szer; K McCaul; A A Morley
Journal:  Blood       Date:  1996-06-15       Impact factor: 22.113

2.  Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia.

Authors:  Forida Y Mortuza; Mary Papaioannou; Ilidia M Moreira; Luke A Coyle; Paula Gameiro; Domenica Gandini; H Grant Prentice; Anthony Goldstone; A Victor Hoffbrand; Letizia Foroni
Journal:  J Clin Oncol       Date:  2002-02-15       Impact factor: 44.544

3.  Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults.

Authors:  D Hoelzer; E Thiel; H Löffler; T Büchner; A Ganser; G Heil; P Koch; M Freund; H Diedrich; H Rühl
Journal:  Blood       Date:  1988-01       Impact factor: 22.113

4.  Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value.

Authors:  María-Belén Vidriales; José J Pérez; Maria Consuelo López-Berges; Norma Gutiérrez; Juana Ciudad; Paulo Lucio; Lourdes Vazquez; Ramón García-Sanz; Maria Consuelo del Cañizo; Javier Fernández-Calvo; Fernando Ramos; M Jesús Rodríguez; M José Calmuntia; Ana Porwith; Alberto Orfao; Jesús F San-Miguel
Journal:  Blood       Date:  2003-02-13       Impact factor: 22.113

5.  A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969.

Authors:  J Gaynor; D Chapman; C Little; S McKenzie; W Miller; M Andreeff; Z Arlin; E Berman; S Kempin; T Gee
Journal:  J Clin Oncol       Date:  1988-06       Impact factor: 44.544

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.